AMG 386

AMG 386 is a peptibody that binds to and inhibits angiopoietin 1 and 2. It is being investigated as a cancer treatment. AMG 386 has a new mechanism of action different from other anti-angiogenesis drugs: it inhibits angiogenesis by preventing interaction between angiopoietins and Tie2 receptor tyrosine kinases. AMG 386 is being tested in combinations with many other drugs including sorafenib and sunittinib in Phase II trials.

Manufacturer: AMGEN, home page: http://www.amgen.com/
information at the manufacturer website: AMG 386

Click here to download results of a completed Phase I trial.

Link here to a current Phase II trial for which GIST patients may be eligible.

Link to abstract: First-in-human study of AMG 386, a selective angiopoietin1/2-neutralizing peptibody, in adult patients with advanced solid tumors. (ASCO 2007 meeting abstract 3522)

The following free-access paper describes involvement of angiopoietin and tie targets in GISTs:
Expression of angiopoietin-1, 2 and 4 and Tie-1 and 2 in gastrointestinal stromal tumor, leiomyoma and schwannoma.
Nakayama T, Inaba M, Naito S, Mihara Y, Miura S, Taba M, Yoshizaki A, Wen CY, Sekine I.
World J Gastroenterol. 2007 Sep 7;13(33):4473-9.